- Home
- ANNX vs MTLS Comparison
ANNX vs MTLS Comparison
Compare ANNX & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- MTLS
- Stock Information
- Founded
- ANNX 2011
- MTLS 1990
- Country
- ANNX United States
- MTLS Belgium
- Employees
- ANNX N/A
- MTLS N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- MTLS Computer Software: Prepackaged Software
- Sector
- ANNX Health Care
- MTLS Technology
- Exchange
- ANNX Nasdaq
- MTLS Nasdaq
- Market Cap
- ANNX 362.4M
- MTLS N/A
- IPO Year
- ANNX 2020
- MTLS 2014
- Fundamental
- Price
- ANNX $1.93
- MTLS $4.92
- Analyst Decision
- ANNX Strong Buy
- MTLS Buy
- Analyst Count
- ANNX 7
- MTLS 1
- Target Price
- ANNX $15.80
- MTLS $9.50
- AVG Volume (30 Days)
- ANNX 1.7M
- MTLS 207.4K
- Earning Date
- ANNX 03-03-2025
- MTLS 04-24-2025
- Dividend Yield
- ANNX N/A
- MTLS N/A
- EPS Growth
- ANNX N/A
- MTLS 106.79
- EPS
- ANNX N/A
- MTLS 0.24
- Revenue
- ANNX N/A
- MTLS $276,182,835.00
- Revenue This Year
- ANNX N/A
- MTLS $6.55
- Revenue Next Year
- ANNX N/A
- MTLS $9.21
- P/E Ratio
- ANNX N/A
- MTLS $21.06
- Revenue Growth
- ANNX N/A
- MTLS 4.15
- 52 Week Low
- ANNX $1.93
- MTLS $4.70
- 52 Week High
- ANNX $7.85
- MTLS $9.69
- Technical
- Relative Strength Index (RSI)
- ANNX 30.11
- MTLS 31.96
- Support Level
- ANNX $2.18
- MTLS $5.01
- Resistance Level
- ANNX $2.75
- MTLS $5.25
- Average True Range (ATR)
- ANNX 0.25
- MTLS 0.17
- MACD
- ANNX -0.01
- MTLS 0.09
- Stochastic Oscillator
- ANNX 0.00
- MTLS 16.92
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.